Seres Therapeutics MCRB 深 沪
已收盘 10-09 16:00:00 美东时间
2.71
+0.080
+3.04%
华盛通- 最 高2.75
- 今 开2.65
- 成交量 7.94万股
- 最 低 2.58
- 昨 收 2.63
- 总市值 2722.14万
- 52周最高 29.98
- 市盈率 静 4.22
- 换手率 0.79%
- 52周最低 2.42
- 委 比 81.86%
- 总股本 1004.48万
- 历史最高 1040.00
- 量 比 0.77
- 振 幅 6.46%
- 历史最低 2.42
- 每 手 1
- 风险率 5.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics granted stock options to purchase 4,200 shares of common stock to two new employees under its 2022 Inducement Plan. The options have an exercise price of $5.72 per share, vesting 25% after one year and 6.25% every three months thereafter. The company focuses on developing live biotherapeutics to address unmet needs in oncology and inflammatory diseases. For more information, visit www.serestherapeutics.com.
09-08 22:00
Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units
SERES THERAPEUTICS, INC. $300,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the se...
08-14 05:21
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share from the same period last year. The company reported quarterly sales of $736.000 t...
08-05 19:29
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes
Seres Therapeutics ( ($MCRB) ) has issued an update. On July 31, 2026, Seres Th...
08-05 04:30
Seres Therapeutics reports positive SER-155 trial results
Seres Therapeutics ( ($MCRB) ) has provided an announcement. On July 8, 2026, S...
07-08 20:30
Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events Observed
The study (NCT06801067), conducted at MSK, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases, evaluated SER-155 in 15 patients with moderate-to-severe (Grade 2- 3) irEC, which affects approximately 25% of all immune checkpoint inhibitor (ICI) th...
07-08 19:04
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Seres Therapeutics announced positive top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC). In the trial conducted at Memorial Sloan Kettering Cancer Center (MSK), 80% of participants achieved an immunosuppressive-free clinical response at Day 15, with no serious adverse events related to SER-155 observed. The drug demonstrated robust engraftment a...
07-08 11:00
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
